论文部分内容阅读
目的评价聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法聚乙二醇干扰素α-2a(派罗欣)联合利巴韦林(800~1 200mg/d)治疗58例慢性丙型肝炎患者,疗程48周,分别于治疗4、12、24和48周及治疗结束后24周评价疗效,并观察药物副作用。结果 RVR:36例(62.1%)EVR:18例(31.0%),SLVR:3例(5.2%),ETVR54例(93.1%),SVR:52例(89.7%);HCV RNA高水平组和低水平组之间持续应答率分别为66.7%和50.0%,差异有统计学意义(P<0.05)。结论在慢性丙型肝炎患者的治疗中SVR54(93.1%),HCV RNA低水平组的疗效优于高水平组。
Objective To evaluate the clinical efficacy of pegylated interferon combined with ribavirin in the treatment of chronic hepatitis C Methods 58 patients with chronic hepatitis C were treated with peginterferon alfa-2a (PEGASYS) combined with ribavirin (800-1 200 mg / d) for 48 weeks. The patients were treated for 4, 12, 24 and 48 weeks and 24 weeks after the end of treatment efficacy evaluation, and observe the side effects of drugs. RESULTS: RVR was found in 36 (62.1%) EVRs: 18 (31.0%), SLVRs in 3 (5.2%), ETVRs in 54 (93.1%) and SVRs in 52 (89.7% The sustained response rates between the two groups were 66.7% and 50.0%, respectively, with significant differences (P <0.05). Conclusions The efficacy of SVR54 (93.1%) and HCV RNA low level group is superior to high level group in the treatment of chronic hepatitis C patients.